Fig 1: hsa-let-7a-2 bound to the intracellular third loop of AGTR2. (A) A schematic diagram of the extracellular and intracellular loops of AGTR2, including the names and sequences of the synthetic loop peptides. (B) hsa-let-7a-2 binding to the different loops of AGTR2 was examined by MST assay, with the synthetic loop peptides as the receptors and hsa-let-7a-2 as the ligand. Data are presented as means ± SD; n = 3 experiments.
Fig 2: Hsa-let-7a-2 negatively regulated Ang II-AGTR2 induced RhoA phosphorylation. (A) Under AGTR1 inhibition, the effect of hsa-let-7a-2 or hsa-let-7a-1/3 overexpression on RhoA serine phosphorylation in Dicer-/- cells was examined. ** P < 0.01 vs. p-CON. (B) RhoA serine phosphorylation was examined in Dicer-/-AGTR1-/- cells overexpressing hsa-let-7a-2 or hsa-let-7a-1/3. ** P < 0.01 vs. p-CON. (C) The changes in Ang II-induced RhoA serine phosphorylation were examined in AGTR1-/- hsa-let-7a-2+/- cells. *P < 0.01 vs. AGTR1-/-. n = 4-8 experiments.
Fig 3: Hsa-let-7a-2 negatively regulated Ang II-AGTR2 related cAMP and SHP-1 signals. (A) Under AGTR1 inhibition with losartan and adenylate cyclase stimulation with forskolin, the intracellular cAMP level was examined after Ang II treatment in cells overexpressing hsa-let-7a-2 (p-hsa-let-7a-2) or control plasmid (p-CON). ** P < 0.01 vs. p-CON. (B) Under the same conditions, Ang II-induced cAMP alterations were examined in Dicer-/- cells overexpressing hsa-let-7a-2 or hsa-let-7a-1/3. ** P < 0.01 vs p-CON. (C) Dicer-/-AGTR1-/- double-knockout cells overexpressing hsa-let-7a-2 or hsa-let-7a-1/3 were pretreated with forskolin and the Ang II-induced cAMP level was measured. * P < 0.05 vs. p-CON. (D) AGTR1-/-hsa-let-7a-2+/- cells and AGTR1-/- cells were pretreated with forskolin and the Ang II-induced cAMP level was compared. ** P < 0.01 vs. AGTR1-/-. (E) Under AGTR1 inhibition with losartan, the Ang II-induced SHP-1 activity was examined in Dicer-/- cells overexpressing hsa-let-7a-2 or hsa-let-7a-1/3. ** P < 0.01 vs. p-CON. (F) Effect of hsa-let-7a-2 or hsa-let-7a-1/3 on Ang II-induced SHP-1 activity in Dicer-/-AGTR1-/- cells. ** P < 0.01 vs. p-CON. (G) Knockdown of hsa-let-7a-2+/- enhanced SHP-1 activity in AGTR1-/- cells. ** P < 0.01 vs. AGTR1-/-. n = 4-8 experiments.
Fig 4: Non-competitive binding of hsa-let-7a-2 with AGTR2. (A) The kinetics of pre-miRNA binding to AGTR2 assayed by microscale thermophoresis (MST), with purified AGTR2-GFP protein as the receptor and hsa-let-7a-1, 2, and 3 as the ligands. (B) The binding kinetics of AGTR2 with its inhibitor, PD123319, as a positive control. (C, D) Competitive inhibition assay performed with [125-I]-sar1-Ile8-angiotensin II as a radioligand (C) or fluorescent ligand (D) to confirm the binding kinetics. Data are presented as means ± SD; n = 3 experiments.
Fig 5: Diagram of findings. Hsa-let-7a-2 not only serves as the pre-miRNA of hsa-let-7a-5p and hsa-let-7a-2-3p, but also binds to the intracellular third loop of AGTR2 and negatively regulates AGTR2 signals and the related biological processes.
Supplier Page from OriGene Technologies for MIRLET7A2 Human MicroRNA Expression Plasmid (MI0000061)